- •Cerebral gray matter volume is a sensitive and clinically relevant measurement of assessing the neuroprotective effect of disease-modifying therapies in multiple sclerosis.
- •Gray matter atrophy is more predictive of conversion from clinically isolated syndrome to multiple sclerosis than white matter disease.
- •Gray matter atrophy has been more strongly associated with cognitive impairment and disability progression than white matter disease.
- •In this pilot study, glatiramer acetate was associated with preservation of cerebral gray matter and whole brain volumes.
Background and purpose
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.J. Neurol. Sci. Oct 2015; 357: 8-18https://doi.org/10.1016/j.jns.2015.07.014
- Lifespan normative data on rates of brain volume changes.Neurobiol. Aging. 2019; 09: 30-37https://doi.org/10.1016/j.neurobiolaging.2019.05.010
- Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options.Auto Immun Highlights. Dec 2019; 10: 7https://doi.org/10.1186/s13317-019-0117-5
- Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis.J. Neurol. Neurosurg. Psychiatry. Nov 2009; 80: 1218-1223https://doi.org/10.1136/jnnp.2008.154732
- The measurement and clinical relevance of brain atrophy in multiple sclerosis.Lancet Neurol. Feb 2006; 5: 158-170https://doi.org/10.1016/S1474-4422(06)70349-0
- The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.Neuroimage. Jul 15 2005; 26: 1068-1077https://doi.org/10.1016/j.neuroimage.2005.03.008
- Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.Brain. May 2004; 127: 1101-1107https://doi.org/10.1093/brain/awh126
- Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype.AJNR Am. J. Neuroradiol. Feb 2005; 26: 341-346
- Hippocampal and deep gray matter nuclei atrophy is relevant for explaining cognitive impairment in MS: a multicenter study.AJNR Am. J. Neuroradiol. Jan 2017; 38: 18-24https://doi.org/10.3174/ajnr.A4952
- A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis.N. Engl. J. Med. Aug 13 1987; 317: 408-414https://doi.org/10.1056/NEJM198708133170703
- Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group.Neurology. Jul 1995; 45: 1268-1276https://doi.org/10.1212/wnl.45.7.1268
- Glatiramer acetate in multiple sclerosis: a review.CNS Drug Rev. 2007; 13: 178-191https://doi.org/10.1111/j.1527-3458.2007.00010.x
- Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.Proc. Natl. Acad. Sci. U. S. A. Jun 20 2000; 97: 7452-7457https://doi.org/10.1073/pnas.97.13.7452
- European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer acetate study group.Ann. Neurol. Mar 2001; 49: 290-297
- Center MSSGatMA. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple sclerosis study group and the MRI analysis center.Mult. Scler. Feb 2001; 7: 33-41https://doi.org/10.1177/135245850100700107
- A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.Mult. Scler. Jun 2006; 12: 309-320https://doi.org/10.1191/135248506ms1318oa
- Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.Mult. Scler. May 2007; 13: 502-508https://doi.org/10.1177/1352458506070704
- Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 multiple sclerosis study group.Mult. Scler. Aug 2000; 6: 255-266https://doi.org/10.1177/135245850000600407
- Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.Neurology. Apr 27 2004; 62: 1432-1434https://doi.org/10.1212/01.wnl.0000120663.85143.b3
- Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.Mult. Scler. 2017; 23: 818-829https://doi.org/10.1177/1352458516664033
- Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.Mult Scler Relat Disord. Jan 2019; 27: 305-311https://doi.org/10.1016/j.msard.2018.11.009
- Rate of brain atrophy in benign vs early multiple sclerosis.Arch. Neurol. Feb 2009; 66: 234-237https://doi.org/10.1001/archneurol.2008.567
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria".Ann. Neurol. Dec 2005; 58: 840-846https://doi.org/10.1002/ana.20703
- Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy.J. Magn. Reson. Imaging. Feb 2002; 15: 203-209https://doi.org/10.1002/jmri.10053
- A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.Int J Neurosci. May 2017; 127: 396-403https://doi.org/10.1080/00207454.2016.1185421
- Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.AJNR Am. J. Neuroradiol. Jun-Jul 2004; 25: 985-996
- Connecting white matter injury and thalamic atrophy in clinically isolated syndromes.J. Neurol. Sci. Jul 15 2009; 282: 61-66https://doi.org/10.1016/j.jns.2009.02.379
- Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.Ann. Neurol. Sep 2001; 50: 389-400https://doi.org/10.1002/ana.1123
- Gray matter involvement in multiple sclerosis.Neurology. Feb 27 2007; 68: 634-642https://doi.org/10.1212/01.wnl.0000250267.85698.7a
- Cortical lesions in multiple sclerosis.Nat. Rev. Neurol. Aug 2010; 6: 438-444https://doi.org/10.1038/nrneurol.2010.93
- Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study.Neurol Neuroimmunol Neuroinflamm. 2019; 6 (e587)https://doi.org/10.1212/NXI.0000000000000587
- 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.Mult. Scler. 2020; 26: 177-187https://doi.org/10.1177/1352458519885106
- Decreased microglial activation in MS patients treated with glatiramer acetate.J. Neurol. Jun 2012; 259: 1199-1205https://doi.org/10.1007/s00415-011-6337-x
- Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".Neurology. Aug 28 2001; 57: 731-733https://doi.org/10.1212/wnl.57.4.731